• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov4
KalVista Pharma to release FY2025 Q3 earnings on November 11 Pre-Market EST, forecast revenue USD 4.2 M, EPS USD -1.02
00:08
Sep29
KalVista Pharmaceuticals Proposes $110 Million Convertible Senior Notes Offering
20:28
Sep26
KalVista to Present New Data on EKTERLY for HAE at German Allergy Congress
11:00
Sep24
KalVista Pharmaceuticals Announces $110 Million Convertible Debt Offering, Shares Drop 10.3%
20:26
Sep19
KalVista Pharmaceuticals Obtains EU and Swiss Approval for EKTERLY® and Plans for Market Launch
11:00
Sep11
KalVista Pharma released FY2026 Q1 earnings on September 11 Pre-Market EST, actual revenue USD 1.426 M (forecast USD 2.089 M), actual EPS USD -1.1233 (forecast USD -0.955)
13:30

Schedules & Filings

Schedules
Filings
Sep11
Earning Release(EST)

FY2026 Q1 Earning Release (USD) Revenue 1.426 M, Net Income -60.1 M, EPS -1.1233

Jul10
Earning Release(EST)

FY2025 Q4 Earning Release (USD) Net Income -52.23 M, EPS -0.9845

Mar12
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -48.51 M, EPS -0.9215

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SEVNR
0.0280
+218.18%
+0.019
SMX
141.000
+141.07%
+82.510
PLRZ
14.500
+104.51%
+7.410
PMI
3.690
+82.67%
+1.670
SNCR
8.710
+64.34%
+3.410
PMCB
1.210
+54.22%
+0.425
QCLS
6.920
+48.18%
+2.250
ANPA
21.860
+40.67%
+6.320
HYNE
14.000
+40.00%
+4.000
ASTX
46.070
+36.50%
+12.320
View More